CMS Targets 15% Medicare Lab Fee Cuts, Threatening DGX & LH Revenue

The Centers for Medicare & Medicaid Services (CMS) plans annual reimbursement cuts of up to 15% for clinical lab fees starting January 1, 2027. This move aims to align Medicare payments with private insurers, potentially saving $1 billion annually 🔗.

Key implications:

• Impacted Companies: Quest Diagnostics (DGX) and Labcorp (LH) are most exposed, as a substantial portion of their revenue comes from Medicare-reimbursed clinical testing 🔗.
• Phased Cuts: Reductions are capped at 15% annually through 2029, leading to significant cumulative cuts 🔗.
• Regulatory Shift: CMS states Medicare has overpaid labs by ~16% compared to private insurers, signaling a major policy correction 🔗.